“Mitch is an ideal addition to our board because of his considerable expertise in developing and bringing revolutionary new products to the aesthetic dermatology market,” said Darrin Uecker, president and CEO. “His experience will be a significant asset as we are working to introduce our CellFX System into this market later in 2019.”
Levinson, 58, has more than 25 years of experience bringing novel medical technologies to the market, including over a decade in the aesthetics procedure market. Levinson previously founded and served as CEO and CSO of Zeltiq Aesthetics from 2005 to 2010, overseeing the development and facilitating the early commercial launch of its flagship CoolSculpting procedure. Prior to Zeltiq, he served as the initial vice president of Research and Development for Thermage from 2000 to 2005, where he built the R&D organization and led the development of Thermage’s novel skin tightening technology. Levinson is currently a board member and chief technology officer of Cerebrotech, a neurotechnology device company focused on the development of portable neurotechnology solutions, that he founded during 2010.
Levinson previously served on the Pulse Biosciences board from January 2015 to November 2017, during which time the company conducted its initial public offering and commenced clinical studies. He also currently serves on the board of directors of ConnectWell, a provider of digital health and wellness content.
Levinson earned a bachelor of science degree in mechanical engineering from University of California at San Diego, and a master of science degree in computer systems from the University of Phoenix. He also is an inventor on 45 issued U.S. patents.
Pulse Biosciences is a medical therapy company bringing to market its proprietary CellFX System. The company’s CellFX System provides a precise, non-thermal delivery of nanosecond duration energy pulses that impact cells in treated tissue while sparing non-cellular tissue. This unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane, initiating a cascade of events within the cell that results in regulated cell death. The novel characteristics of the Company’s CellFX System has the potential to significantly benefit patients across multiple medical applications, including dermatology, the company’s first planned commercial application. In pre-clinical studies, Nano-Pulse Stimulation (NPS) technology platform has demonstrated an ability to induce immunogenic cell death in several cancer cell lines. The company believes its NPS technology platform may play a role in immuno-oncology as a focal tumor treatment that can initiate an adaptive immune response.
Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) are for investigational use only.